‘Modeling studies have shown that widespread access to PrEP could reduce fresh HIV infections, and thus the scale of the global HIV epidemic, around the world substantially,’ the press release says, adding, ‘The FDA’s decision on TDF/FTC as PrEP could help pave just how for global health funders and developing countries to intensify their planning for execution’ . This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent information service, is a scheduled system of the Kaiser Family Foundation, a nonpartisan healthcare policy research company unaffiliated with Kaiser Permanente..The subjects in the analysis achieved effective exchange to a permanent implant with the same basic safety profile as saline cells expanders. The full total results will be submitted to the U.S. Food and Drug Administration within the Firm's 510 dossier which is planned to be sent to the FDA shortly. Jeffrey Ascherman, M.D., chief of plastic principal and surgery investigator for the XPAND Trial from Columbia Presbyterian Medical Center in New York, stated, ‘AeroForm has demonstrated that it may be used as successfully as saline expanders in the treating women who ‘re going through two-stage reconstructive medical procedures carrying out a mastectomy.